19:01 , Aug 31, 2018 |  BC Week In Review  |  Company News

Urovant gets rights to gene therapy for overactive bladder

Ion Channel Innovations LLC (Ardsley, N.Y.) granted Urovant Sciences Ltd. (Basel, Switzerland) rights to develop and commercialize hMaxi-K, a gene therapy in development for overactive bladder. Next year, Urovant plans to start a Phase II...
20:44 , Aug 28, 2018 |  BC Extra  |  Company News

Roivant units Urovant, Dermavant in deals as NEA’s Torti joins ‘vant’ team

Two Roivant Sciences GmbH (Basel, Switzerland) subsidiaries struck deals on Tuesday, with Urovant Sciences gaining rights to a gene therapy for overactive bladder and Dermavant Sciences receiving a $100 million investment tied to its tapinarof....
17:47 , Jun 28, 2018 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: SNPs SNPs on 124 genomic loci could help predict the risk of myopia and other ocular refractive errors. Genome-wide association studies (GWAS) in 255,925 individuals identified associations between ocular refractive errors including myopia and...
20:40 , Jan 5, 2018 |  BC Week In Review  |  Company News

Mallinckrodt acquiring Sucampo

Mallinckrodt plc (NYSE:MNK) said it will acquire Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) for $18 per share in a deal the companies say values Sucampo at $1.2 billion. The price is a 6% premium to Sucampo's close...
23:19 , Dec 26, 2017 |  BC Extra  |  Company News

Mallinckrodt acquiring Sucampo

Mallinckrodt plc (NYSE:MNK) said Tuesday it will acquire Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) for $18 per share in a deal the companies say values Sucampo at $1.2 billion. The price is a 6% premium to Sucampo's...
07:00 , Mar 16, 2015 |  BC Week In Review  |  Clinical News

Unoprostone isopropyl: Phase III data

Top-line data from a double-blind, Japanese Phase III trial in about 180 patients showed that 0.15% unoprostone isopropyl eye drops missed the primary endpoint of improving mean retinal sensitivity at 4 central points from baseline...
07:00 , Sep 22, 2014 |  BC Week In Review  |  Clinical News

GAL-021: Clinical trial data

A double-blind, placebo-controlled, crossover, proof-of-concept (POC) trial in 12 healthy volunteers showed that IV GAL-021 protected against alfentanil-induced respiratory depression without affecting analgesia. Specifically, low-dose GAL-021 led to a significant improvement in minute ventilation compared...
08:00 , Dec 23, 2013 |  BC Week In Review  |  Clinical News

Amitiza lubiprostone: Phase III started

Sucampo and Takeda began a double-blind, placebo-controlled, international Phase III trial to evaluate 12 or 24 µg oral lubiprostone twice daily for 12 weeks in >500 patients ages 6-17 years with functional constipation. The companies'...
08:00 , Nov 11, 2013 |  BC Week In Review  |  Clinical News

Unoprostone isopropyl: Completed Phase III enrollment

Sucampo said R-Tech Ueno completed enrollment of 180 patients in a double-blind, placebo-controlled, Japanese Phase III trial evaluating 0.15% unoprostone isopropyl eye drops for 52 weeks. The trial includes a 52-week open-label study following the...
07:00 , Oct 28, 2013 |  BC Week In Review  |  Clinical News

Amitiza lubiprostone: Phase III data

Data from 124 patients ages 3-17 years with functional constipation defined as <3 SBMs per week in an open-label Phase III trial showed that lubiprostone was well tolerated and increased SBM frequency. In children <6...